Donanemab, a new drug developed by Eli Lilly for the treatment of early forms of Alzheimer's disease, has received a favorable opinion from the EMA committee, recommending its authorization. The drug, which is intended for patients who are non-carriers or heterozygous for apolipoprotein E ε4, has been shown in clinical trials to slow the progression of cognitive impairment. The drug will be available as an infusible solution, and common side effects include amyloid-associated imaging abnormalities and headache. The final authorization decision rests with the European Commission.
Sources
Un nou tratament pentru boala Alzheimer în stadii timpurii, aproape de autorizare în UE
Un medicament pentru tratamentul bolii Alzheimer în stadii timpurii, aproape de autorizare în UE
Un medicament pentru tratamentul bolii Alzheimer în stadii timpurii, aproape de autorizare în UE
Latest News
10:46
Negotiations on regulating autonomous weapons end without agreement in Geneva
10:37
Bitcoin fell below $56,000 / Investors fear risks in the AI sector
10:24
Washington Post: Trump's adviser received hundreds of thousands of dollars for activities related to Romania, as part of a $3.4 million lobbying contract
10:14
Iran calls for guarantees for serious negotiations with the US, while Trump says the deal Tehran wants is unacceptable
09:55
Russian attack on the city of Kryvyi Rih: 2 dead, 55 injured
See more news